Sagimet Biosciences Inc. ((Sagimet, NASDAQ:SGMT), a clinical-stage biopharmaceutical company developing novel fatty acid synthase (FASN) inhibitors designed to target dysfunctional metabolic and fibrotic pathways, today

SGMT

Morgan Stanley Upgrades Colgate-Palmolive On Attractive Growth Opportunity

By Shivani Kumaresan

January 30, 2:08 PM

Morgan Stanley analyst Dara Mohsenian upgraded Colgate-Palmolive Company (NYSE:CL) from Equal-Weight to Overweight with a price target of $82. The analyst believes…

Cancer Diagnostic Firm Theralink To Merge With IMAC Holdings

By Vandana Singh

May 23, 2:44 PM

Theralink Technologies Inc and IMAC Holdings Inc (NASDAQ:BACK) have entered into a merger agreement under which Theralink will merge with a newly-formed…

BACK

BTIG Downgrades Redwood Trust to Neutral

Related Posts

Citigroup Upgrades LexinFintech Holdings to Buy, Raises Price Target to $3.6

Sagimet Biosciences Announces Completion Of Phase 1 Hepatic Impairment Study With FASN Inhibitor Denifanstat

Morgan Stanley Upgrades Colgate-Palmolive On Attractive Growth Opportunity

Cancer Diagnostic Firm Theralink To Merge With IMAC Holdings